Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Akorn is a drug manufacturers-specialty & generic business based in the US. Akorn stocks (AKRX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Akorn employs 2,227 staff and has a trailing 12-month revenue of around $721.3 million.
|52-week range||$0.00 - $0.00|
|50-day moving average||$0.04|
|200-day moving average||$0.18|
|Wall St. target price||$2.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.82|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Akorn stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Akorn's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Akorn's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $46.9 million.
The EBITDA is a measure of a Akorn's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$721.3 million|
|Gross profit TTM||$252.7 million|
|Return on assets TTM||-0.94%|
|Return on equity TTM||-231.8%|
|Market capitalisation||$12 million|
TTM: trailing 12 months
We're not expecting Akorn to pay a dividend over the next 12 months.
Over the last 12 months, Akorn's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akorn's is 1.1428. This would suggest that Akorn's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Akorn, Inc. , a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products.
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.Read more…
Here are some investment ideas that could do well despite rising interest rates.Read more…
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.Read more…
Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PXE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing FCG stock, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.